We provide you with 20 years of free, institutional-grade data for ANL stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of ANL. Explore the full financial landscape of ANL stock.
| Reported Date | CIK | Ticker | Type |
|---|
Adlai Nortye Ltd.(NASDAQ:ANL) 
Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent ...
Website: https://www.adlainortye.com/
Founded: 2004
IPO Price: $23 (Sep 29, 2023)
Sector: TECHNOLOGY
Industry: GENERAL
Share this website to your friends
The information provided in this report about ANL stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.